Kane’s DispersinB passes biocompatibility tests

Kane Biotech’s (TSX-V:KNE) DispersinB’s topical wound spray has passed FDA-recommended cytotoxicity, primary skin irritation and genotoxicity tests, with two remaining biocompatibility studies currently in progress. “Biocompatibility is critical to the commercial development of a topical wound care product and these results confirm that DispersinB spray is non-cytotoxic, non-irritant, non-mutagenic and non-genotoxic,” CSO Dr. Sri Madhyastha [...]

Kane gets DispersinB from biotech plants

Kane Biotech (TSX-V:KNE) has confirmed the invention of biotech plants producing DispersinB antibiofilm enzyme, representing a proof of concept for developing bacterial disease-resistant agricultural crops. The Company said DispersinB-expressing plants are resistant to plant pathogens due to their ability to inhibit and disrupt biofilms. In addition, this biotech plant can also be used as a [...]

Australia issues patent for Kane’s DispersinB

Kane Biotech (TSXV:KNE) received patent protection in Australia for its DispersinB anti-biofilm technology, the third country to cover the technology. The patent claims the gene encoding DispersinB enzyme and also the amino acid sequence of the enzyme, as well as method of production, pharmaceutical composition, methods of administration and applications in medical devices. Biofilms develop [...]